CClinicalTrials.gg
CompletedNCT03444532Updated May 5, 2020

Feasibility Study Testing a Sleep Intervention in Prostate Cancer Patients With Insomnia

An interventional study of 12-week aerobic exercise and cognitive-behavioral therapy in Cancer of Prostate and Insomnia, sponsored by Danish Cancer Society. Completed at 1 site in Denmark. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-05.

Sponsored by Danish Cancer Society · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Study summary

This study of a randomized controlled trial aims to evaluate the feasibility of a 12-week sleep program and the randomized controlled trial research procedure. In total 20 participants will be recruited and randomized to the intervention or control group.

Read the detailed description

This feasibility study of a randomized controlled trial, aims to evaluate the feasibility of a 12-week sleep program consisting on aerobic exercise and cognitive-behavioral therapy. In this study the investigators wish to evaluate the program as well as the randomized controlled trial research procedure.

In total 20 participants will be recruited and randomized to either the intervention group (n=10) or control group (n=10).The intervention group will participate in two exercise sessions each week and four sessions based on cognitive-behavioral therapy for insomnia.

02

Conditions studied

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Inclusion criteria

  • Prostate cancer
  • Receiving treatment with androgen deprivation therapy or in combination with chemotherapy
  • Insomnia
  • Over 18-yers old
  • Understand oral and written Danish
  • Written informed consent

Exclusion criteria

Exclusion Criteria:

  • Medical assessment that does not allow aerobic exercise
  • Severe cognitive problems
  • Night work during the interventions period
  • Exercise training more than three times a week
04

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    12-week aerobic exercise and cognitive-behavioral therapy

    12-week aerobic exercise, two times per week, and cognitive-behavioral therapy for insomnia in total four sessions

    Behavioral: 12-week aerobic exercise and cognitive-behavioral therapy

  • No intervention
    Control group

    Patients assigned to the control group will receive usual care

Interventions

  • Behavioral12-week aerobic exercise and cognitive-behavioral therapy

    12-week intervention of aerobic exercise training and four session of cognitive-behavioral therapy

05

What researchers measure

Primary outcomes

  1. Sleep

    Measured by actigraphy, to investigate change in sleep from baseline to 12 weeks and the difference in change between intervention - and the control group

    Time frame: Change from baseline sleep at 12 weeks

Secondary outcomes

  1. Cardiorespiratory fitness

    Measured by watt max test, to investigate change from baseline to 12 weeks and the difference in change between intervention and the control group

    Time frame: Baseline, 12-weeks

  2. Fatigue

    Measured by the multidimensional fatigue inventory, to investigate change in fatigue from baseline to 12 weeks and 6 months follow up and the difference in change between intervention - and the control group

    Time frame: Baseline, 12 weeks, 6 month

  3. Physical activity

    Measured by the Physical activity Questionnaire to investigate change in physical activity from baseline to 12 weeks and 6 months follow up and the difference in change between intervention - and the control group

    Time frame: Baseline, 12 weeks, 6 month

  4. Depression

    Measured by the Patient Health Questionnaireto, to investigate change in depression from baseline to 12 weeks and 6 months follow up and the difference in change between intervention - and the control group

    Time frame: Baseline, 12 weeks, 6 month

  5. Anxiety

    Measured by the Generalized Anxiety Disorder Questionnaireto, to investigate change in anxiety from baseline to 12 weeks and 6 months follow up and the difference in change between intervention - and the control group

    Time frame: Baseline, 12 weeks, 6 month

  6. Stress

    Measured by Perceived Stress Scale to investigate change in stress from baseline to 12 weeks and 6 months follow up and the difference in change between intervention - and the control group

    Time frame: Baseline, 12 weeks, 6 month

  7. Quality of life

    Measured by European Organization for Research and Treatment Cancer, to investigate change in quality of life from baseline to 12 weeks and 6 months follow up and the difference in change between intervention - and the control group

    Time frame: Baseline, 12 weeks, 6 month

  8. Sleep quality

    Measured by Pittsburgh Sleep Quality Index, to investigate change in sleep quality from baseline to 12 weeks and 6 months follow up and the difference in change between intervention - and the control group

    Time frame: Baseline, 12 weeks, 6 month

  9. Sleep pattern

    Measured by a sleep diary, to investigate change in sleep pattern from baseline to 12 weeks and 6 months follow up and the difference in change between intervention - and the control group

    Time frame: Baseline, 12 weeks, 6 month

  10. Insomnia

    Measured by Insomnia Severity Index, to investigate change in insomnia from baseline to 12 weeks and 6 months follow up and the difference in change between intervention - and the control group

    Time frame: Baseline, 12 weeks, 6 month

  11. Physical activity

    Measured by actigraphy, to investigate change in physical activity from baseline to 12 weeks and the difference in change between intervention - and the control group

    Time frame: Baseline, 12 weeks

06

Study locations

1 site
  • Oncology Department
    Næstved, Denmark
07

Registry details

Key details

Study ID
NCT03444532
Lead sponsor
Danish Cancer Society
Responsible party
Christoffer Johansen (Professor, Danish Cancer Society) — Principal investigator
First posted
Feb 23, 2018
Start date
Mar 2, 2018
Primary completion
Mar 31, 2019
Completion
May 31, 2019
Last update
May 5, 2020

Study contacts

Christoffer Johansen, PhD, Dr.Med
principal investigator · Danish Cancer Society Research Center
Katrine Løppenthin, PhD
principal investigator · Danish Cancer Society Research Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion